{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:23:34Z","timestamp":1775132614915,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","award":["DE-AC02-05CH11231"],"award-info":[{"award-number":["DE-AC02-05CH11231"]}],"id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bmc.2025.118182","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T20:13:00Z","timestamp":1744056780000},"page":"118182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and identification of brain-penetrant, potent, and selective 1,3-oxazole-based cholesterol 24-hydroxylase (CH24H) inhibitors"],"prefix":"10.1016","volume":"124","author":[{"given":"Yoshiteru","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsurou","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Skene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118182_b0005","doi-asserted-by":"crossref","unstructured":"Guengerich, F. P. Human Cytochrome P450 Enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 4th ed.; Ortiz de Montellano, P. R., Ed.; Vol. 2; Springer International Publishing, 2015; pp 523\u2013785. DOI: 10.1007\/978-3-319-12108-6_9.","DOI":"10.1007\/978-3-319-12108-6_9"},{"key":"10.1016\/j.bmc.2025.118182_b0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fmicb.2019.00691","article-title":"The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors","volume":"10","author":"Zhang","year":"2019","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.bmc.2025.118182_b0015","doi-asserted-by":"crossref","first-page":"10964","DOI":"10.1021\/acscatal.8b03401","article-title":"Mechanisms of Cytochrome P450-Catalyzed Oxidations","volume":"8","author":"Guengerich","year":"2018","journal-title":"ACS Catalysis"},{"key":"10.1016\/j.bmc.2025.118182_b0020","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1021\/acs.jmedchem.1c00864","article-title":"Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)","volume":"64","author":"Koike","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0025","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.5b00851","article-title":"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys","volume":"58","author":"Martin","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0030","doi-asserted-by":"crossref","first-page":"31783","DOI":"10.1074\/jbc.M110.143313","article-title":"Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain","volume":"285","author":"Mast","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0035","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiv228","article-title":"VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis","volume":"212","author":"Lepesheva","year":"2015","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.bmc.2025.118182_b0040","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1021\/acs.jmedchem.4c00303","article-title":"Identification of Potent and Selective Inhibitors of Acanthamoeba: Structural Insights into Sterol 14alpha-Demethylase as a Key Drug Target","volume":"67","author":"Hargrove","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0045","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1021\/acs.biochem.7b00334","article-title":"High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4","volume":"56","author":"Sevrioukova","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0050","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1021\/jm400288z","article-title":"Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir","volume":"56","author":"Sevrioukova","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0055","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.bmcl.2014.04.024","article-title":"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors","volume":"24","author":"Rafferty","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.bmc.2025.118182_b0060","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1021\/jp802087w","article-title":"How do azoles inhibit cytochrome P450 enzymes? A density functional study","volume":"112","author":"Balding","year":"2008","journal-title":"The Journal of Physical Chemistry. A"},{"key":"10.1016\/j.bmc.2025.118182_b0065","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/ci2000506","article-title":"Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen","volume":"51","author":"Leach","year":"2011","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.bmc.2025.118182_b0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cbi.2011.05.001","article-title":"The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1","volume":"193","author":"Jones","year":"2011","journal-title":"Chemico-Biological Interactions"},{"key":"10.1016\/j.bmc.2025.118182_b0075","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/jm801331y","article-title":"The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists","volume":"52","author":"Laurence","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0080","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.96.13.7238","article-title":"cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain","volume":"96","author":"Lund","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bmc.2025.118182_b0085","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s13311-019-00731-6","article-title":"Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases","volume":"16","author":"Petrov","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bmc.2025.118182_b0090","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1073\/pnas.93.18.9799","article-title":"Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation","volume":"93","author":"Lutjohann","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bmc.2025.118182_b0095","doi-asserted-by":"crossref","first-page":"22980","DOI":"10.1074\/jbc.M303415200","article-title":"Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover","volume":"278","author":"Lund","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0100","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/bph.15191","article-title":"Neuro-oxysterols and neuro-sterols as ligands to nuclear receptors, GPCRs, ligand-gated ion channels and other protein receptors","volume":"178","author":"Wang","year":"2021","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.bmc.2025.118182_b0105","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/epi.17062","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice","volume":"62","author":"Hawkins","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.bmc.2025.118182_b0110","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/epi.17232","article-title":"Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor","volume":"63","author":"Nishi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.bmc.2025.118182_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105835","article-title":"Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy","volume":"173","author":"Salamone","year":"2022","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.bmc.2025.118182_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109310","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice","volume":"222","author":"Barker-Haliski","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmc.2025.118182_b0125","doi-asserted-by":"crossref","first-page":"17081","DOI":"10.1038\/s41598-020-74036-6","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice","volume":"10","author":"Nishi","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.bmc.2025.118182_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.bmc.2025.118182_b0135","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1073\/pnas.0803717105","article-title":"Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain","volume":"105","author":"Mast","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bmc.2025.118182_b0140","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1021\/acs.jmedchem.1c01898","article-title":"Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors","volume":"65","author":"Kajita","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114612","article-title":"Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H)","volume":"240","author":"Ikeda","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","article-title":"Role of pharmacokinetics and metabolism in drug discovery and development","volume":"49","author":"Lin","year":"1997","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.bmc.2025.118182_b0155","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.bmcl.2019.06.040","article-title":"Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research","volume":"29","author":"Zhao","year":"2019","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.bmc.2025.118182_b0160","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jhet.5570350654","article-title":"A facile one-pot synthesis of 2,5-disubstituted oxazoles using iodobenzene diacetate","volume":"35","author":"Varma","year":"1998","journal-title":"Journal of Heterocyclic Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0165","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/acschemneuro.1c00866","article-title":"Molecular Basis of the Recognition of Cholesterol by Cytochrome P450 46A1 along the Major Access Tunnel","volume":"13","author":"Shi","year":"2022","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.bmc.2025.118182_b0170","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/ejoc.200400066","article-title":"Three Chloro(trifluoromethyl)pyridines as Model Substrates for Regioexhaustive Functionalization","volume":"2004","author":"Cottet","year":"2004","journal-title":"European Journal of Organic Chemistry"},{"key":"10.1016\/j.bmc.2025.118182_b0175","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1016\/j.tet.2009.06.023","article-title":"Synthesis of 2-TIPS-oxazol-5-ylboronic acid pinacol ester: efficient route to 5-(het)aryloxazoles via Suzuki cross-coupling reaction","volume":"65","author":"Primas","year":"2009","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2025.118182_b0180","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1107\/S0907444908004046","article-title":"Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1","volume":"64","author":"White","year":"2008","journal-title":"Acta Crystallographica. Section D, Biological Crystallography"},{"key":"10.1016\/j.bmc.2025.118182_b0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods in Enzymology"},{"key":"10.1016\/j.bmc.2025.118182_b0190","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1107\/S0021889897006766","article-title":"MOLREP: an Automated Program for Molecular Replacement","volume":"30","author":"Vagin","year":"1997","journal-title":"Journal of Applied Crystallography"},{"key":"10.1016\/j.bmc.2025.118182_b0195","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1107\/S0907444994003112","volume":"50","year":"1994","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.bmc.2025.118182_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.bmc.2025.118182_b0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.bmc.2025.118182_b0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.bmc.2025.118182_b0215","first-page":"2","article-title":"The PyMOL Molecular Graphics System","volume":"2","author":"Schr\u00f6dinger","year":"2018","journal-title":"Version"},{"key":"10.1016\/j.bmc.2025.118182_b0220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions","volume":"8","author":"Wallace","year":"1995","journal-title":"Protein Engineering, Design & Selection"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:21:44Z","timestamp":1745497304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":44,"alternative-id":["S0968089625001233"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118182","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and identification of brain-penetrant, potent, and selective 1,3-oxazole-based cholesterol 24-hydroxylase (CH24H) inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118182"}}